Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

A method-of-treating a living animal for alleviation of a condition treatable by a NMDA antagonist comprising the step of administering to the living animal an amount of a compound selected from those of formula I:

• wherein:
• R* is —(A)n—(CR1R2)m—NR3R4,
• n+m=0, 1, or 2,
• A is selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R3 and R4 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or together form alkylene (C2-C10) or alkenylene (C2-C10) or together with the N form a 3-7-membered azacycloalkane or azacycloalkene, including substituted (alkyl (C1-C6), substituted alkenyl (C2-C6)) 3-7-membered azacycloalkane or azacycloalkene,
• R5, Rp, Rq, Rr, and Rs are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or R5 may combine with the carbon atom of W to which it is attached and an adjacent carbon atom of the group R* to form a double bond, or R5 combine with the carbon atom of W to which it is attached and an adjacent ring carbon atom to form a double bond, or Rp, Rq, Rr, and Rs independently may combine with the carbon to which it is attached and the next adjacent carbon to form a double bond, or Rp, Rq, Rr, and Rs independently may form a double bond with U or with Y to which it is attached, and
• provided that U-V-W-X-Y-Z is selected from:
• cyclohexane,
• cyclohex-1-ene,
• cyclohex-2-ene,
• cyclohex-3-ene,
• cyclohex-1,3-diene,
• cyclohex-1,4-diene,
• cyclohex-1,5-diene,
• cyclohex-2,4-diene, and
• cyclohex-2,5-diene,
• and provided that when U—Z equals cyclohexane, then at least one of —(A)n—(CR1R2)m—, R3, R4, R5, Rp, Rq, Rr is linear or branched lower alkenyl (C2-C6) or linear or branched lower alkynyl ((C22-C6),
• its optical isomers and pharmaceutically-acceptable acid or base addition salts thereof, which is effective for alleviation of said condition.

A method-of-treating a living animal for alleviation of a condition treatable by a compound selected for its immunomodulatory, anti-malarial, anti-Borna virus, or anti-Hepatitis C, anti-trypanosomal, and anti-HSV efficacy, comprising the step of administering to the living animal an amount of a compound selected from those of formula I:

• wherein:
• R* is —(A)n—(CR1R2)m—NR3R4,
• n+m=0, 1, or 2,
• A is selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R3 and R4 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or together form alkylene (C2-C10) or alkenylene (C2-C10) or together with the N form a 3-7-membered azacycloalkane or azacycloalkene, including substituted (alkyl (C1-C6), substituted alkenyl (C2-C6)) 3-7-membered azacycloalkane or azacycloalkene,
• R5, Rp, Rq, Rr, and Rs are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or R5 may combine with the carbon atom of W to which it is attached and an adjacent carbon atom of the group R* to form a double bond, or R5 may combine with the carbon atom of W to which it is attached and an adjacent ring carbon atom to form a double bond or Rp, Rq, Rr, and Rs independently may combine with the carbon to which it is attached and the next adjacent carbon to form a double bond, or Rp, Rq, Rr, and Rs independently may form a double bond with U or with Y to which it is attached, and
• provided that U—V—W—X—Y—Z is selected from:
• cyclohexane,
• cyclohex-1-ene,
• cyclohex-2-ene,
• cyclohex-3-ene,
• cyclohex-1,3-diene,
• cyclohex-1,4-diene,
• cyclohex-1,5-diene,
• cyclohex-2,4-diene, and
• cyclohex-2,5-diene,
• and provided that when U—Z equals cyclohexane, then at least one of —(A)n—(CR1R2)m—, R3, R4, R5, Rp, Rq, Rr is linear or branched lower alkenyl (C2-C6) or linear or branched lower alkynyl (C2-C6),
• its optical isomers and pharmaceutically-acceptable acid or base addition salts thereof, which is effective for alleviation of said condition.

A method-of-treating a living animal for alleviation of a condition treatable by an NMDA antagonist selected from the group consisting of excitotoxicity selected from iscbaemia during stroke, trauma, hypoxia, hypoglycemia, glaucoma, and hepatic encephalopathy,

• chronic neurodegenerative diseases selected from Alzheimer's disease, vascular dementia, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, AIDS-neurodegeneration, olivopontocerebellar atrophy, Tourette's syndrome, motor neurone disease, mitochondrial dysfunction, Korsakoff syndrome, and Creutzfeldt-Jakob disease,
• other disorders related to long term plastic changes in the central nervous system selected from chronic pain, drug tolerance, dependence and addiction (e.g., opioids, cocaine, benzodiazepines, nicotine, and alcohol), and
• epilepsy, tardive dyskinesia, L-DOPA-induced dyskinesia, schizophrenia, anxiety, depression, acute pain, spasticity, and tinnitus,
• comprising the step of administering to the living animal an amount of a compound selected from those of formula I:
• wherein:
• R* is —(A)n—(CR1R2)m—NR3R4,
• n+m=0, 1, or 2,
• A is selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R3 and R4 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or together form alkylene (C2-C10) or alkenylene (C2-C10) or together with the N form a 3-7-membered azacycloallcane or azacycloalkene, including substituted (alkyl (C1-C6), substituted alkenyl (C2-C6)) 3-7-membered azacycloalkane or azacycloalkene,
• R5, Rp, Rq, Rr, and Rs are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or R5 may combine with the carbon atom of W to which it is attached and an adjacent carbon atom of the group R* to form a double bond, or R5 may combine with the carbon atom of W to which it is attached and an adjacent ring carbon atom to form a double bond, Rp, Rq, Rr, and Rs independently may combine with the carbon to which it is attached and the next adjacent carbon to form a double bond, or Rp, Rq, Rr, and Rs independently may form a double bond with U or with Y to which it is attached, and
• provided that U-V-W-X-Y-Z is selected from:
• cyclohexane,
• cyclohex-1-ene,
• cyclohex-2-ene.
• cyclohex-3-ene,
• cyclohex-1,3-diene,
• cyclohex-1,4-diene,
• cyclohex-1,5-diene,
• cyclohex-2,4-diene, and
• cyclohex-2,5-diene,
• and provided that when U—Z equals cyclohexane, then at least one of —(A)n—(CR1R2)m—, R3, R4, R5, Rp, Rq, Rr is linear or branched lower alkenyl (C2-C6) or linear or branched lower alkynyl (C2-C6),
• its optical isomers and pharmaceutically-acceptable acid or base addition salts thereof, which is effective for alleviation of said condition.

A method-of-treating a living animal for alleviation of a condition treatable by a 5HT3 receptor antagonist, comprising the step of administering to the living animal an amount of a compound selected from those of formula I:

• wherein:
• R is —(A)n—(CR1R2)m—NR3R4,
• n+m=0, 1, or 2,
• A is selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R3 and R4 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or together form alkylene (C2-C10) or alkenylene (C2-C10) or together with the N form a 3-7-membered azacycloalkane or azacycloalkene, including substituted (alkyl (C1-C6), substituted alkenyl (C2-C6)) 3-7-membered azacycloalkane or azacycloalkene,
• R5, Rp, Rq, Rr, and Rs are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or R5 may combine with the carbon atom of W to which it is attached and an adjacent carbon atom of the group R* to form a double bond, or R5 may combine with the carbon atom of W to which it is attached and an adjacent ring carbon atom to form a double bond, Rp, Rq, Rr, and Rs independently may combine with the carbon to which it is attached and the next adjacent carbon to form a double bond, or Rp, Rq, Rr, and Rs independently may form a double bond with U or with Y to which it is attached, and
• provided that U—V—W—X—Y—Z is selected from:
• cyclohexane,
• cyclohex-1-ene,
• cyclohex-2-ene,
• cyclohex-3-ene,
• cyclohex-1,3-diene,
• cyclohex-1,4-diene,
• cyclohex-1,5-diene,
• cyclohex-2,4-diene, and
• cyclohex-2,5-diene,
• and provided that when U—Z equals cyclohexane, then at least one —(A)n—(CR1R2)m—, R3, R4, R5, Rp, Rq, Rr is linear or branched lower alkenyl (C2-C6) or linear or branched lower alkynyl (C2-C6),
• its optical isomers and pharmaceutically-acceptable acid or base addition salts thereof, which is effective for alleviation of said condition.

A method-of-treating a living animal for alleviation of a condition treatable by a neuronal nicotinic receptor antagonist, comprising the step of administering to the living animal an amount of a compound selected from those of formula I:

• wherein:
• R* is —(A)n—(CR1R2)m—NR3R4,
• n+m=0, 1, or 2,
• A is selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R3 and R4 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or together form alkylene (C2-C10) or alkenylene (C2-C10) or together with the N form a 3-7-membered azacycloalkane or azacycloalkene, including substituted (alkyl (C1-C6), substituted alkenyl (C2-C6)) 3-7-membered azacycloallcane or azacycloalkene,
• R5, Rp, Rq, Rr, and Rs are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or R5 may combine with the carbon atom of W to which it is attached and an adjacent carbon atom of the group R* to form a double bond, or R5 may combine with the carbon atom of W to which it is attached and an adjacent ring carbon atom to form a double bond, Rp, Rq, Rr, and Rs independently may combine with the carbon to which it is attached and the next adjacent carbon to form a double bond, or Rp, Rq, Rr, and Rs independently may form a double bond with U or with Y to which it is attached, and
• provided that U—V—W—X—Y—Z is selected from:
• cyclohexane,
• cyclohex-1-ene,
• cyclohex-2-ene,
• cyclohex-3-ene,
• cyclohex-1,3-diene,
• cyclohex-1,4-diene,
• cyclohex-1,5-diene,
• cyclohex-2,4-diene, and
• cyclohex-2,5-diene,
• and provided that when U—Z equals cyclohexane, then at least one of —(A)n—(CR1R2)m—, R3, R4, R5, Rp, Rq, Rr is linear or branched lower alkenyl (C2-C6) or linear or branched lower alkynyl (C2-C6),
• its optical isomers and pharmaceutically-acceptable acid or base addition salts thereof, which is effective for alleviation of said condition.

A method-of-treating a living animal for alleviation of a condition treatable by a 5HT3 antagonist selected from the group consisting of anxiety disorders, depressive disorders, Schizophrenia and treatment related psychosis, drug and alcohol abuse disorders, cognitive disorders, Alzheimer's disease, Parkinson's disease, cerebellar tremor, migraine, appetite disorders, inflammatory bowel syndrome (IBS), and eniesis, comprising the step of administering to the living animal an amount of a compound selected from

• those of formula I:
• wherein:
• R* is —(A)n—(CR1R2)m—NR3R4,
• n+m=0, 1, or 2,
• A is selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R3 and R4 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or together form alkylene (C2-C10) or alkenylene (C2-C10) or together with the N form a 3-7-membered azacycloalkane or azacycloalkene, including substituted (alkyl (C1-C6), substituted alkenyl (C2-C6)) 3-7-membered azacycloalkane or azacycloalkene,
• R5, Rp, Rq, Rr, and Rs are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or R5 may combine with the carbon atom of W to which it is attached and an adjacent carbon atom of the group R* to form a double bond, or R5 may combine with the carbon atom of W to which it is attached and an adjacent ring carbon atom to form a double bond, or Rp, Rq, Rr, and Rs independently may combine with the carbon to which it is attached and the next adjacent carbon to form a double bond, or Rp, Rq, Rr, and Rs independently may form a double bond with U or with Y to which it is attached, and
• provided that U—V—W—X—Y—Z is selected from:
• cyclohexane,
• cyclohex-1-ene,
• cyclohex-2-ene,
• cyclohex-3-one,
• cyclohex-1,3-diene,
• cyclohex-1,4-diene,
• cyclohex-1,5-diene,
• cyclohex-2,4-diene, and
• cyclohex-2,5-diene,
• and provided that when U—Z equals cyclohexane, then at least one of —(A)n—(CR1R2)m—, R3, R4, R5, Rp, Rq, Rr is linear or branched lower alkenyl (C2-C6) or linear or branched lower alkynyl (C2-C6),
• its optical isomers and pharmaceutically-acceptable acid or base addition salts thereof, which is effective for alleviation of said condition.

A method-of-treating a living animal for alleviation of a condition treatable by a neuronal nicotinic receptor antagonist selected from the group consisting of Tourette's syndrome, anxiety disorders, Schizophrenia, drug abuse, nicotine abuse, cocaine abuse, dyskinesia (Morbus Huntington, L-DOPA-induced), attention deficit hyperactivity disorder (ADHD), Alzheimer's disease, Parkinson's disease, and pain, comprising the step of administering to the living animal an amount of a compound selected from those of formula I:

• wherein:
• R is —(A)n—(CR1R2)m—NR3R4,
• n+m=0, 1, or 2,
• A is selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R3 and R4 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or together form alkylene (C2-C10) or alkenylene (C2-C10) or together with the N form a 3-7-membered azacycloalkane or azacycloalkene, including substituted (alkyl (C1-C6), substituted alkenyl (C2-C6)) 3-7-membered azacycloalkane or azacycloalkene,
• R5, Rp, Rq, Rr, and Rs are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or R5 may combine with the carbon atom of W to which it is attached and an adjacent carbon atom of the group R* to form a double bond, or R5 may combine with the carbon atom of W to which it is attached and an adjacent ring carbon atom to form a double bond, or Rp, Rq, Rr, and Rs independently may combine with the carbon to which it is attached and the next adjacent carbon to form a double bond, or Rp, Rq, Rr, and Rs independently may form a double bond with U or with Y to which it is attached, and
• provided that U—V—W—X—Y—Z is selected from:
• cyclohexane,
• cyclohex-1-ene,
• cyclohex-2-ene,
• cyclohex-3-ene,
• cyclohex-1,3-diene,
• cyclohex-1,4-diene,
• cyclohex-1,5-diene,
• cyclohex-2,4-diene, and
• cyclohex-2,5-diene,
• and provided that when U—Z equals cyclohexane, then at least one of —(A)n—(CR1R2)m—, R3, R4, R5, Rp, Rq, Rr is linear or branched lower alkenyl (C2-C6) or linear or branched lower alkynyl (C2-C6),
• its optical isomers and pharmaceutically-acceptable acid or base addition salts thereof, which is effective for alleviation of said condition.

A pharmaceutical composition having a compound selected from those of formula I:

• wherein:
• R* is —(A)n—(CR1R2)m—NR3R4,
• n+m=0, 1, or 2,
• A is selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R1 and R2 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6),
• R3 and R4 are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or together form alkylene (C2-C10) or alkenylene (C2-C10) or together with the N form a 3-7-membered azacycloalkane or azacycloalkene, including substituted (alkyl (C1-C6), substituted alkenyl (C2-C6)) 3-7-membered azacycloalkane or azacycloalkene,
• R5 is independently selected from the group consisting of linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or 5 may combine with the carbon atom of W to which it is attached and an adjacent carbon atom of the group R* to form a double bond, or R5 may combine with the carbon atom of W to which it is attached and an adjacent ring carbon atom to form a double bond,
• Rp, Rq, Rr, and Rs are independently selected from the group consisting of hydrogen, linear or branched lower alkyl (C1-C6), linear or branched lower alkenyl (C2-C6), and linear or branched lower alkynyl (C2-C6), or Rp, Rq, Rr, and Rs independently may combine with the carbon to which it is attached and the next adjacent carbon to form a double bond, or Rp, Rq, Rr, and Rs independently may form a double bond with U or with Y to which it is attached,
• provided that U—V—W—X—Y—Z is selected from
• cyclohexane,
• cyclohex-2-ene,
• cyclohex-3-ene,
• cyclohex-1,4-diene,
• cyclohex-1,5-diene,
• cyclohex-2,4-diene, and
• cyclohex-2,5-diene,
• and provided that at least one of Rp, and Rq, are not hydrogen and at least one of Rr, and Rs are not hydrogen,
• and provided that when U—Z equals cyclohexane, then at least one of —(A)n—(CR1R2)m—, R3, R4, R5, Rp, Rq, Rr, and Rs is linear or branched lower alkenyl (C2-C6) or linear or branched lower alkynyl (C2-C6),
• and provided that when U—Z equals cyclohexane, then R5 cannot be hydrogen,
• in combination with one or more pharmaceutically-acceptable diluents, excipients, or carriers.